Page 90 - Read Online

Pippione et al. Steroidogenic enzymes in prostate cancer

82. PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS,
74. Poirier D. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of
review. Expert Opin Ther Pat 2010;20:1123-45. finasteride in men with benign prostatic hyperplasia. 1992. J Urol
75. Day JM, Tutill HJ, Purohit A. 17ss-hydroxysteroid dehydrogenase 2002;167:1102-8.
inhibitors. Minerva Endocrinol 2010;35:87-108. 91. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy
76. Olusanjo MS, Ahmed S. Inhibitors of 17-hydroxysteroid and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2
dehydrogenase type 3 (17-beta-HSD 3). Drugs Future 2009;34:555. (dutasteride) in men with benign prostatic hyperplasia. Urology
77. Ning X, Yang Y, Deng H, Zhang Q, Huang Y, Su Z, Fu Y, Xiang Q, 2002;60:434-41.
Zhang S. Development of 17β-hydroxysteroid dehydrogenase type 92. Faller B, Farley D, Nick H. Finasteride: a slow-binding 5 alpha-
3 as a target in hormone-dependent prostate cancer therapy. Steroids reductase inhibitor. Biochemistry 1993;32:5705-10.
2017;121:10-6. 93. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An
78. Fink BE, Gavai AV, Tokarski JS, Goyal B, Misra R, Xiao HY, overview on 5alpha-reductase inhibitors. Steroids 2010;75:109-53.
Kimball SD, Han WC, Norris D, Spires TE, You D, Gottardis 94. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB,
MM, Lorenzi MV, Vite GD. Identification of a novel series of Hobbs S. Marked suppression of dihydrotestosterone in men with
tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase
dehydrogenase type 3. Bioorg Med Chem Lett 2006;16:1532-6. inhibitor. J Clin Endocrinol Metab 2004;89:2179-84.
79. Vicker N, Sharland CM, Heaton WB, Gonzalez AM, Bailey HV, 95. Salvador JA, Pinto RM, Silvestre SM. Steroidal 5alpha-reductase
Smith A, Springall JS, Day JM, Tutill HJ, Reed MJ, Purohit A, Potter and 17alpha-hydroxylase/17,20-lyase (CYP17) inhibitors useful
BV. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 in the treatment of prostatic diseases. J Steroid Biochem Mol Biol
inhibitors. Mol Cell Endocrinol 2009;301:259-65. 2013;137:199-222.
80. Nashev LG, Schuster D, Laggner C, Sodha S, Langer T, Wolber 96. Holt DA, Levy MA, Oh HJ, Erb JM, Heaslip JI, Brandt M, Lan-
G, Odermatt A. The UV-filter benzophenone-1 inhibits 17beta- Hargest HY, Metcalf BW. Inhibition of steroid 5 alpha-reductase by
hydroxysteroid dehydrogenase type 3: virtual screening as a strategy unsaturated 3-carboxysteroids. J Med Chem 1990;33:943-50.
to identify potential endocrine disrupting chemicals. Biochem 97. Yao Z, Xu Y, Zhang M, Jiang S, Nicklaus MC, Liao C. Discovery of a
Pharmacol 2010;79:1189-99. novel hybrid from finasteride and epristeride as 5α-reductase inhibitor.
81. Schuster D, Kowalik D, Kirchmair J, Laggner C, Markt P, Aebischer- Bioorg Med Chem Lett 2011;21:475-8.
Gumy C, Strohle F, Moller G, Wolber G, Wilckens T, Langer T, 98. Aggarwal S, Thareja S, Bhardwaj TR, Haupenthal J, Hartmann RW,
Odermatt A, Adamski J. Identification of chemically diverse, novel Kumar M. Synthesis and biological evaluation of novel unsaturated
inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 and 5 by carboxysteroids as human 5alpha-reductase inhibitors: a legitimate
pharmacophore-based virtual screening. J Steroid Biochem Mol Biol approach. Eur J Med Chem 2012;54:728-39.
2011;125:148-61. 99. Kim S, Kim Y-U, Ma E. Synthesis and 5α-reductase inhibitory activity
82. Guzi TJ, Liu Y-T, Doll RJ, Saksena A, Girijavallabhan VM, Pachter of C21 steroids having 1,4-diene or 4,6-diene 20-ones and 4-azasteroid
JA. Preparation of 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b] 20-oximes. Molecules 2012;17:355-68.
pyridine derivatives as 17 beta-hydroxysteroid dehydrogenase 100. Al-Mohizea AM, Al-Omar MA, Abdalla MM, Amr AG. 5alpha-
type 3 inhibitors for the treatment of androgen dependent diseases. reductase inhibitors, antiviral and anti-tumor activities of some
Kenilworth, USA; Schering Corporation; 2004. p. 72. steroidal cyanopyridinone derivatives. Int J Biol Macromol
83. Day JM, Foster PA, Tutill HJ, Schmidlin F, Sharland CM, Hargrave 2012;50:171-9.
JD, Vicker N, Potter BV, Reed MJ, Purohit A. STX2171, a 17beta- 101. Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase
hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo inhibition on prostate cancer (Review). Oncol Lett 2014;8:1391-6.
in a novel hormone-dependent prostate cancer model. Endocr Relat 102. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-
Cancer 2013;20:53-64. ARIs) may increase the risk of a more serious form of prostate cancer.
84. Harada K, Kubo H, Tomigahara Y, Nishioka K, Takahashi J, Momose Available from: https://www.fda.gov/Drugs/DrugSafety/ucm258314.
M, Inoue S, Kojima A. Coumarins as novel 17beta-hydroxysteroid htm. [Last accessed on 13 Nov 2017]
dehydrogenase type 3 inhibitors for potential treatment of prostate 103. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I,
cancer. Bioorg Med Chem Lett 2010;20:272-5. Black L, Rittmaster RS. Dutasteride in localised prostate cancer
85. Harada K, Kubo H, Abe J, Haneta M, Conception A, Inoue S, management: the REDEEM randomised, double-blind, placebo-
Okada S, Nishioka K. Discovery of potent and orally bioavailable controlled trial. Lancet 2012;379:1103-11.
17β-hydroxysteroid dehydrogenase type 3 inhibitors. Bioorg Med 104. Schroder F, Bangma C, Angulo JC, Alcaraz A, Colombel M,
Chem 2012;20:3242-54. McNicholas T, Tammela TL, Nandy I, Castro R. Dutasteride treatment
86. Ohno S, Nakajima Y, Nakajin S. Triphenyltin and tributyltin inhibit over 2 years delays prostate-specific antigen progression in patients
pig testicular 17beta-hydroxysteroid dehydrogenase activity and with biochemical failure after radical therapy for prostate cancer:
suppress testicular testosterone biosynthesis. Steroids 2005;70:645-51. results from the randomised, placebo-controlled Avodart After Radical
87. Titus MA, Li Y, Kozyreva OG, Maher V, Godoy A, Smith GJ, Mohler Therapy for Prostate Cancer Study (ARTS). Eur Urol 2013;63:779-
JL. 5α-reductase type 3 enzyme in benign and malignant prostate. 87.
Prostate (Hoboken, NJ, U S) 2014;74:235-49. 105. Ramalingam S, Ramamurthy VP, Njar VC. Dissecting major
88. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme signaling pathways in prostate cancer development and progression:
family: a review of basic biology and their role in human diseases. Mechanisms and novel therapeutic targets. J Steroid Biochem Mol
Adv Urol 2012;2012:530121. Biol 2017;166:16-27.
89. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis 106. Blessing AM, Ganesan S, Rajapakshe K, Ying Sung Y, Reddy Bollu
CJ, Mills GB, Kim J. Androgen regulation of 5alpha-reductase L, Shi Y, Cheung E, Coarfa C, Chang JT, McDonnell DP, Frigo DE.
isoenzymes in prostate cancer: implications for prostate cancer Identification of a novel coregulator, SH3YL1, that interacts with the
prevention. PLoS One 2011;6:e28840. androgen receptor N-terminus. Mol Endocrinol 2015;29:1426-39.
90. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh 107. Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets

358 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017